The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Qlonilik clonidine hydrochloride New formulation or manufacturer | Cmp Dev Llc | 🇺🇸 US 2026-07-29 | Order → | |
| Gwyn Lo ethinyl estradiol, norelgestromin New formulation or manufacturer | Viatris Specialty | 🇺🇸 US 2026-07-28 | Order → | |
| Colchicine Agepha Pharma colchicine | Agepha Pharma s.r.o. | Myocardial Infarction; Stroke; Coronary Artery Disease | 🇪🇺 EU 2026-07-24 | Order → |
| Garzulys insulin aspart-fsan Biosimilar | Emerge Bioscience Pte. Ltd. | 🇺🇸 US 2026-07-24 | Order → | |
| Lytenava bevacizumab-vikg Biosimilar | Outlook Therapeutics, Inc. | 🇺🇸 US 2026-07-24 | Order → | |
| Simtriyo centanafadine hydrochloride New molecular entityPriority review | Otsuka Pharmaceutical Co Ltd | 🇺🇸 US 2026-07-24 | Order → | |
| Tylenol With Naproxen acetaminophen, naproxen sodium New combination | Kenvue Brands | 🇺🇸 US 2026-07-24 | Order → | |
| Jideytro zidesamtinib New molecular entity | Nuvalent | 🇺🇸 US 2026-07-22 | Order → | |
| Etcamah camizestrant Additional monitoring | AstraZeneca AB | Breast Neoplasms | 🇪🇺 EU 2026-07-20 | Order → |
| Air air | Noble Gas Solutions Inc. | 🇺🇸 US 2026-07-19 | Order → | |
| Ablymico liraglutide Additional monitoring | STADA Arzneimittel AG | Obesity; Overweight | 🇪🇺 EU 2026-07-15 | Order → |
| Boey trenibotulinumtoxinE Additional monitoring | AbbVie Limited | Stress, Psychological; Cosmetic Techniques | 🇪🇺 EU 2026-07-15 | Order → |
| Jascayd nerandomilast Additional monitoring | Boehringer Ingelheim International GmbH | Idiopathic Pulmonary Fibrosis | 🇪🇺 EU 2026-07-15 | Order → |
| Lipfendra enlicitide decanoate New molecular entityPriority review | Msd | 🇺🇸 US 2026-07-15 | Order → | |
| Liraglutide STADA liraglutide Additional monitoring | STADA Arzneimittel AG | Diabetes Mellitus | 🇪🇺 EU 2026-07-15 | Order → |
| Vijoice alpelisib OrphanConditionalAdditional monitoring | Novartis Europharm Limited | Genetic Diseases, Inborn; Growth Disorders | 🇪🇺 EU 2026-07-15 | Order → |
| Vislyfa ranibizumab BiosimilarAdditional monitoring | Lupin Europe GmbH | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2026-07-15 | Order → |
| Revtorpyk gedatolisib New molecular entityPriority review | Celcuity | 🇺🇸 US 2026-07-14 | Order → | |
| Zyogreen indocyanine green New dosage form | Provepharm Sas | 🇺🇸 US 2026-07-10 | Order → | |
| Sarclisa Escena isatuximab-irfc New biologic | Sanofi-Aventis U.S. Llc | 🇺🇸 US 2026-07-09 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.